Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?

Area of Science:

• Neuro-oncology
• Cancer Genomics
• Molecular Pathology

Background:

• Medulloblastoma is a rare posterior cranial fossa malignancy.
• Current WHO classification recognizes medulloblastoma as heterogeneous, comprising distinct molecular subgroups.
• Adult medulloblastoma is an orphan entity with limited clinical trial data compared to pediatric cases.

Purpose of the Study:

• To review recent advances in targeted therapy for medulloblastoma.
• To highlight the application of new biological insights into therapeutic strategies.
• To address the challenge of translating cancer genomics into effective treatments for adult medulloblastoma.

Main Methods:

• Review of recent scientific literature on medulloblastoma biology and targeted therapies.
• Analysis of advances in understanding molecular subgroups and driver alterations.
• Focus on the translation of genomic discoveries into clinical applications.

Main Results:

• Medulloblastoma exhibits significant molecular heterogeneity, influencing clinical behavior and treatment response.
• Distinct gene expression profiles and driver alterations define specific subgroups.
• Progress in understanding disease biology is paving the way for novel targeted therapeutics.

Conclusions:

• Targeted therapies based on molecular profiling offer a promising avenue for improving adult medulloblastoma prognosis.
• Addressing treatment-related toxicities is a key goal alongside enhancing efficacy.
• Continued research integrating genomics and clinical practice is crucial for advancing medulloblastoma treatment.